Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMRT Combined With Concurrent Chemotherapy and Anti-EGFR Monoclonal Antibody in Locally Advanced Oropharyngeal Carcinoma Resistant to Induction Chemotherapy: a Multicenter Prospective Phase II Study.

NCT04508829 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04508829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04508829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMRT Combined With Concurrent Chemotherapy and Anti-EGFR Monoclonal Antibody in Locally Advanced Oropharyngeal Carcinoma Resistant to Induction Chemotherapy: a Multicenter Prospective Phase II Study.
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2016
Completion date
December 1, 2023
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oropharyngeal carcinoma